Rua Bioscience Limited logo

Rua receives capital from existing shareholders

Capital Raise7 August 2025RUAHealthcare

7th August 2025


FOR PUBLIC RELEASE


Rua Bioscience receives capital from existing shareholders to support significant sales

growth

Tairawhiti, New Zealand – Rua Bioscience is pleased to announce it has secured a total of $1.2

million in new funding through a combination of equity and existing lending instruments. This

capital has been provided by several key shareholders, reflecting their continued confidence in

Rua’s vision and strategic direction.

Today, the Board resolved to issue up to 16,000,000 new ordinary shares at an issue price of

$0.03 per share. These equity securities will be issued under the company’s existing placement

capacity.

The funds raised will be used to accelerate sales growth in our key markets of Germany,

Australia, New Zealand and the UK, and support near-term working capital requirements.

This investment represents a strong endorsement of Rua’s strategy by key shareholders as we

continue to introduce our unique genetics from Te Tairawhiti to patients around the world



ENDS  


The person who authorised this announcement:

Paul Naske

Chief Executive Officer

paul.naske@ruabio.com

+64 21 445154

---

Corporate Action Notice

Page 1 of 3


Section 1: Issuer information (mandatory)

Name of issuer Rua Bioscience Limited

Class of Financial Product Ordinary shares

NZX ticker code RUA

ISIN (If unknown, check on NZX

website)

NZRUAE0004S1

Name of Registry Computershare Investor Services Limited

Type of corporate action

(Please mark with an X in the relevant

box/es)

Share Purchase

Plan/retail offer

Renounceable

Rights issue or

Accelerated

Offer


Capital

reconstruction

Non-

Renounceable

Rights issue or

Accelerated

Offer


Call Bonus issue

Placement X

Record date NA

Ex Date (one business day before the

Record Date)

NA

Currency NZD

External approvals required before offer

can proceed on an unconditional basis?

No

Details of approvals required NA

Section 7: Placement

(delete full section if not applicable, or mark rows as N/A if not applicable)*

Number of Equity Securities to be

issued

16,000,000

Issue price per Equity Security $0.03

Maximum dollar amount of Equity

Securities to be issued

1


$480,000

Proposed issue date 8/8/2025


1


Where the issue price per Equity Security is not fixed, and the number of Equity Securities to be issued is not known, the Issuer

should instead indicate the maximum dollar amount of Equity Securities to be issued.

2 of 3
Existing holders eligible to

participate

2


Y (limited)

Related Parties eligible to

participate

3


Y

Basis upon which participation by

existing Equity Security holders will

be determined

Placement to large existing shareholders based on

confidential discussions with a limited number of existing

investors.

Purpose(s) for which the Issuer is

issuing the Equity Securities

To fund short-term and immediate business operating

funding requirements.

Reason for placement rather than a

pro-rata rights issue or an offer

under a Share Purchase Plan in

which the Issuer’s existing Equity

Security holders would have been

eligible to participate

Due to urgency of funding requirements for working

capital and in order to facilitate a further update to all

shareholders on Rua’s broader capital raising strategy

which will allow for existing Equity Security holder

participation.

Equity Securities to be issued

subject to voluntary escrow

Nil

Number and class of Equity

Securities to be issued that will be

subject to voluntary escrow and the

date from which they will cease to

be escrowed

NA

Section 8: Lead Manager and Underwriter (mandatory)

Lead Manager(s) appointed N

Name of Lead Manager(s) NA

Fees, commission or other

consideration payable to Lead

Manager(s) for acting as lead

manager(s)

Nil

Underwritten N

Name of Underwriter(s) NA

Extent of underwriting (i.e. amount

or proportion of the offer that is

underwritten)

NA

Fees, commission or other

consideration payable to

Underwriter(s) for acting as

underwriter(s)

NA


2

Issuers should answer Y if existing shareholders are eligible to participate even if their participation is subject to satisfaction of

eligibility criteria applying to the placement generally, such as the offer only being made to investors in certain jurisdictions or with a

certain status, such as wholesale, sophisticated or professional investors only.


3

Issuers should answer Y if there are no restrictions on participation by Related Parties as a result of their status as Related Parties

(i.e. restrictions on participation applying to the placement generally should be disregarded).

3 of 3
Summary of significant events that

could lead to the underwriting

being terminated

NA

Section 9: Authority for this announcement (mandatory)

Name of person authorised to make this

announcement

Paul Naske

Contact person for this announcement Paul Naske

Contact phone number 021 445 154

Contact email address paul.naske@ruabio.com

Date of release through MAP 7/8/2025

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.